Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation: Chinese Sub‐Cohort Analysis of a Phase III , Randomized, Double‐Blind , Placebo‐controlled Trial

Controlled Trial ◽

Cohort Analysis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793516776 ◽

2016 ◽

Author(s):

Robin Spiller

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793463618 ◽

2012 ◽

Author(s):

David Alpers

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

312 Efficacy and Safety of ASP7147, a Bombesin-2 Receptor Antagonist, in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): Results of a Multicenter, Double-Blind, Placebo-Controlled Trial

Gastroenterology ◽

10.1016/s0016-5085(15)30241-9 ◽

2015 ◽

Vol 148 (4) ◽

pp. S-69 ◽

Cited By ~ 2

Author(s):

Anthony Lembo ◽

James Huber ◽

Robert M. Schinagl ◽

Stephen J. Waters ◽

M. Scott Harris

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

The American Journal of Gastroenterology ◽

10.1038/ajg.2012.254 ◽

2012 ◽

Vol 107 (11) ◽

pp. 1702-1712 ◽

Cited By ~ 239

Author(s):

William D Chey ◽

Anthony J Lembo ◽

Bernard J Lavins ◽

Steven J Shiff ◽

Caroline B Kurtz ◽

...

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Trial in China and Other Regions

10.26226/morressier.57c5383cd462b80296c9b7be ◽

2016 ◽

Author(s):

Yunsheng Yang

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

The American Journal of Gastroenterology ◽

10.14309/00000434-201410002-01831 ◽

2014 ◽

Vol 109 ◽

pp. S541 ◽

Cited By ~ 16

Author(s):

Philip Miner ◽

Robert DeLuca ◽

Marianela La Portilla ◽

Eveline Padila ◽

William Koltun ◽

...

Keyword(s):

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging ◽

The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial

Journal of Neurogastroenterology and Motility ◽

10.5056/jnm19160 ◽

2020 ◽

Vol 26 (1) ◽

pp. 117-127 ◽

Cited By ~ 1

Author(s):

Seung Yong Shin ◽

Bong Ki Cha ◽

Won-Seok Kim ◽

Jae Yong Park ◽

Jeong Wook Kim ◽

...

Keyword(s):

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial

Scientific Reports ◽

10.1038/s41598-018-21241-z ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 16

Author(s):

Yi-Yuan Sun ◽

Ming Li ◽

Yue-Yue Li ◽

Li-Xiang Li ◽

Wen-Zhe Zhai ◽

...

Keyword(s):

Controlled Trial ◽

Fecal Microbiota ◽

Clostridium Butyricum ◽

Double Blind ◽

Double Blind Placebo ◽

S1298 AST-120 (Spherical Carbon Adsorbent) Improves Pain and Bloating in a Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Non-Constipating Irritable Bowel Syndrome (IBS)

Gastroenterology ◽

10.1016/s0016-5085(10)61014-1 ◽

2010 ◽

Vol 138 (5) ◽

pp. S-223 ◽

Cited By ~ 2

Author(s):

Jan F. Tack ◽

M.S. Harris ◽

Scott Proksch ◽

Jeffrey D. Bornstein ◽

Philip B. Miner

Keyword(s):

Controlled Trial ◽

Carbon Adsorbent ◽

Double Blind ◽

Double Blind Placebo ◽

Spherical Carbon ◽